Opsy Holding

Opsy Holding Current Assets

The Current Assets of Opsy Holding (OPSYH.SL) as of Oct 29, 2026 is -1,000.00 SEK. In the previous year, Current Assets was 1,000.00 SEK — a change of -200.00% (lower).

Current Assets

-1,000.00SEK

YoY

-200.00%

Last updated:

Current Assets of Opsy Holding is 2025 -1,000.00 SEK. Current Assets of Opsy Holding was 2024 1,000.00 SEK. It decreases by -200.00% lower compared to the previous year.

The Opsy Holding Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
22.05 M SEK
Jan 1, 2019
16.55 M SEK
Jan 1, 2020
24.11 M SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
1,000.00 SEK
Jan 1, 2025
-1,000.00 SEK
The Opsy Holding Current Assets history
YEARCurrent AssetsYoY
-1,000.00SEK-200.00%
1,000.00SEK—
0.00SEK—
0.00SEK—
0.00SEK-100.00%
24.11 MSEK+45.70%
16.55 MSEK-24.94%
22.05 MSEK-43.92%
39.31 MSEK+103.31%
19.34 MSEK+14.46%
16.89 MSEK-52.48%
35.55 MSEK+343.91%
8.01 MSEK+92.59%
4.16 MSEK+281.12%
1.09 MSEK-87.03%
8.41 MSEK+1,260.84%
618,000.00SEK-76.61%
2.64 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opsy Holding Stock analysis

What does Opsy Holding do? Opsy Holding AB develops a software platform for insurance companies and medical advisors, focusing on anti-metastatic therapies related to the Wnt-5a protein. The company's products target the metastatic process through specific small molecules that interact with Wnt-5a mechanisms. Insurance companies and medical advisors purchase the platform to integrate advanced therapeutic insights into their services. The company's primary market segment consists of healthcare technology providers seeking innovative solutions for metastasis research. Opsy Holding AB's software platform is designed to support medical advisors and insurance firms in evaluating small molecules that specifically interact with the Wnt-5a protein's role in metastasis. The company's focus on Wnt-5a mechanisms positions its products for specialized healthcare applications. Insurance companies use the platform to enhance their risk assessment models with advanced therapeutic data. The company's business model centers on providing a technology platform that bridges medical research and insurance applications. By targeting the Wnt-5a protein's role in metastasis, Opsy Holding AB offers a niche solution for healthcare technology providers. The platform's value lies in its ability to connect specific small molecule evaluations with practical applications in insurance and medical advisory services. Opsy Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opsy Holding stock

Current Assets of Opsy Holding is -1,000.00 SEK in 2025.

Current Assets of Opsy Holding changed from 1,000.00 SEK to -1,000.00 SEK, representing a -200.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Opsy Holding since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Opsy Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Opsy Holding

All Key Metrics — Opsy Holding